BellBrook Labs Launches New Streamlined Website
MADISON, Wis. (PRWEB) August 21, 2018 -- Whether it be online or through a suite of high throughput screening (HTS) solutions, Bellbrook Labs is dedicated to offering customers a successful experience. When browsing the new site in search of information regarding biochemical assays, visitors will find a seamless transition between products, with relevant details such as technical manuals, application notes, and instrument compatibility readily available.
The new capabilities will allow BellBrook to respond faster to the changing trends in drug discovery. Opportunities are now available for scientists to interact directly through the web interface with the click of a mouse. The new bellbrooklabs.com will also make purchasing product SKUs fast and easy, providing more time for scientists to work on experiments, and less time purchasing reagents.
BellBrook’s goal is for scientists who visit the website with the desire to learn more about HTS solutions, confidence that the assays will help accelerate their drug discovery. With a seamless, continuous flow, Bellbrook Labs hopes that any visitor will find learning about HTS products easier than ever before. To visit the new website or learn more go to bellbrooklabs.com or call 608-443-2400.
About BellBrook Labs: BellBrook Labs is dedicated to accelerating drug discovery and biological research by providing innovative high throughput screening solutions. BellBrook’s core technology Transcreener is a universal, homogenous biochemical assay platform based on detection of nucleotides that makes it easy to screen thousands of different enzymes. These include validated targets like kinases and phosphodiesterases, as well as emerging targets like ATPases, GTPases, methyltransferases, and glycosyltransferases. Detection reagents from BellBrook Labs help researchers progress toward more effective therapies for cancer and other debilitating diseases.
Justin Brink, BellBrook Labs, http://www.bellbrooklabs.com, +1 (608) 227-4519, [email protected]
Share this article